Abstract
Therapeutic vaccines represent an option for active immunotherapy of cancers. The immunotherapy of cancer has been practiced already in the 19th century. With the advances in the fields of immunology, genomics and production technologies, it started to be accepted as an attractive investment option among the innovators. The early trends in the development of cancer vaccines, or immunotherapeutics, as referred to by some professional circles, were towards the autologous or personalized products, while recently they shift more towards the generalized types of vaccines. Number of various different antigens and adjuvants are used in the design of cancer vaccines. There is a small portfolio of already registered and commercialized cancer therapeutic vaccines, but the pipeline of Phase II and III products looks promising. The accumulation of clinical expertise offers a hope for understanding of the mechanisms, therapeutic regimes, combinations with other therapies, and safety of the immunotherapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
